Feline Calicivirus-Associated Limping Syndrome (Acute Polyarthritis)

Feline Calicivirus-Associated Limping Syndrome, also known as Acute Polyarthritis or "Limping Syndrome," is a distinct clinical manifestation of feline calicivirus (FCV) infection characterized by sudden-onset lameness, fever, and joint pain affecting multiple limbs. Unlike the classic upper respiratory presentation of FCV, this syndrome predominantly involves the musculoskeletal system, resulting from viral replication within synovial tissues and the surrounding periarticular structures. It is observed both as a natural infection sequela and, notably, as a recognized adverse reaction following administration of modified-live FCV vaccines. The condition tends to be self-limiting in the majority of affected cats, though it can cause significant temporary morbidity, and a virulent systemic strain (VS-FCV) has been associated with more severe and potentially fatal outcomes.

Causative Agent

Feline calicivirus is a small, non-enveloped, single-stranded positive-sense RNA virus belonging to the family Caliciviridae, genus Vesivirus. FCV exhibits significant genetic and antigenic diversity due to a high mutation rate, and multiple strains circulate in cat populations worldwide. The limping syndrome is associated with specific strains that demonstrate a tropism for synovial tissue in addition to the classic mucosal epithelial tropism.

Pathogenesis of Synovial Involvement

Following oronasal exposure, FCV replicates initially in the epithelium of the oral cavity and upper respiratory tract. In strains associated with limping syndrome, hematogenous spread occurs via viremia, allowing the virus to seed distant tissues including synovium, cartilage, and periarticular soft tissues. Within the synovial membrane, viral replication triggers a robust local inflammatory cascade involving infiltration of neutrophils and mononuclear cells, resulting in synovitis and periarticular edema. Prostaglandin release and cytokine upregulation (including interleukins and tumor necrosis factor) contribute to the characteristic fever, pain, and swelling observed clinically.

Vaccine-Associated Limping Syndrome

A particularly well-recognized context for this syndrome is post-vaccination limping, occurring most commonly in kittens receiving modified-live FCV vaccines. In this scenario, attenuated vaccine strains replicate at low levels and can disseminate to synovial tissues, causing a transient polyarthritis typically appearing 1–5 days post-vaccination and resolving spontaneously within 1–2 weeks. This adverse event is considered uncommon but well-documented in veterinary practice.

Virulent Systemic FCV (VS-FCV)

An important and more severe variant involves virulent systemic strains of FCV, which can cause multi-organ involvement including hemorrhagic edema, skin ulceration, and high mortality. While limping may occur in these patients, it is overshadowed by systemic signs. Outbreaks of VS-FCV have been reported primarily in adult, vaccinated cats in shelter or hospital environments.

Contributing Factors

• ·Age: Young kittens and adolescent cats appear more susceptible to the limping syndrome form
• ·Immunological status: Immunocompromised or maternally antibody-naïve cats may be at greater risk
• ·Crowding and stress: Dense housing environments (shelters, multi-cat households) facilitate FCV transmission and contribute to strain diversity

Clinical Diagnosis

Diagnosis is often made presumptively based on history and physical examination findings. Key diagnostic clues include acute-onset polyarthritis in a young cat with fever, a recent vaccination history (for vaccine-associated cases), or known exposure to other FCV-infected cats. Careful joint palpation to localize swelling and pain to multiple joints helps distinguish this condition from traumatic monoarthritis or other orthopedic disease.

Laboratory Findings

Routine bloodwork, while not diagnostic, helps characterize severity and rule out concurrent disease:

• ·

  Complete Blood Count (CBC):

  • ·WBC: Variable; may show leukocytosis with neutrophilia during active infection, or occasionally a transient leukopenia
  • ·HCT (Hematocrit): Usually within normal limits in uncomplicated cases; mild anemia may be seen in severe or prolonged disease
  • ·PLT (Platelets): Typically normal; thrombocytopenia may be observed in VS-FCV cases with systemic involvement
• ·

  Serum Biochemistry:

  • ·ALT: Mildly elevated in some cases, suggesting hepatocellular involvement during viremia; markedly elevated in VS-FCV
  • ·GLOB (Globulins): May be elevated due to acute-phase inflammatory response
  • ·ALB (Albumin): Usually normal; hypoalbuminemia can occur in VS-FCV with protein-losing processes
  • ·BUN/CREA: Generally normal in limping syndrome; elevated in VS-FCV cases with renal involvement
  • ·TBIL (Total Bilirubin): Usually normal; hyperbilirubinemia is a feature of severe VS-FCV

Synovial Fluid Analysis

Arthrocentesis of affected joints typically yields a cloudy, yellow-tinged fluid. Cytology reveals an inflammatory exudate predominantly composed of non-degenerate neutrophils and macrophages, with cell counts often exceeding 5,000–10,000 cells/µL (reference range typically <3,000 cells/µL). Bacterial culture of synovial fluid is negative, confirming non-septic (immune-mediated or viral) polyarthritis.

Virology and PCR

• ·RT-PCR (Reverse Transcriptase Polymerase Chain Reaction): Oropharyngeal or conjunctival swabs are submitted for FCV RT-PCR, which is the gold-standard confirmatory test. In post-vaccination cases, distinguishing vaccine strains from field strains via PCR or sequencing may be possible in specialized laboratories.
• ·Virus Isolation: Available in research or reference laboratory settings; less practical clinically
• ·Serology: Rising titers of FCV-neutralizing antibodies on paired serum samples (2–3 weeks apart) can support recent infection, though interpretation is complicated by vaccination history

Radiography

Radiographs of affected joints typically show soft tissue swelling without bony erosion or joint destruction, consistent with acute synovitis. This helps differentiate FCV-associated polyarthritis from immune-mediated erosive polyarthritis (e.g., feline rheumatoid-like arthritis) and neoplastic joint disease.

Differential Diagnosis

• ·Calicivirus-unrelated immune-mediated polyarthritis (erosive or non-erosive)
• ·Septic arthritis (bacterial)
• ·Trauma (fracture, ligamentous injury)
• ·Mycoplasma-associated polyarthritis
• ·FeLV- or FIV-associated arthropathy
• ·Feline infectious peritonitis (FIP) with joint involvement

General Approach

In uncomplicated FCV-associated limping syndrome, treatment is primarily supportive, as the condition is typically self-limiting and resolves within 1–2 weeks without specific antiviral therapy.

Supportive Care

• ·Rest and environmental modification: Restricting activity, providing low-sided litter boxes, soft bedding, and easy access to food and water to minimize pain-related disability
• ·Fluid support: Subcutaneous or intravenous fluids may be necessary in cats with severe anorexia, dehydration, or fever-related fluid losses

Analgesia and Anti-inflammatory Therapy

• ·NSAIDs: Meloxicam (0.1 mg/kg orally once, then 0.05 mg/kg once daily) is the most commonly used analgesic/anti-inflammatory agent in cats. It should be used with caution, for the shortest effective duration, and is contraindicated in cats with renal compromise or dehydration. Baseline renal parameters (BUN, CREA) should be evaluated before use.
• ·Buprenorphine: Opioid analgesia (0.01–0.02 mg/kg buccal transmucosally every 6–8 hours) can be used for cats with moderate to severe pain who may not tolerate or who are contraindicated for NSAIDs
• ·Corticosteroids: Generally avoided in FCV infection due to immunosuppressive effects that may prolong viral shedding or worsen systemic disease; their use is reserved for refractory immune-mediated arthritis confirmed by extensive diagnostic workup

Nutritional Support

• ·Appetite stimulants (e.g., mirtazapine 1.875 mg/cat orally every 48–72 hours, or transdermal formulation) may be beneficial in cats with prolonged anorexia
• ·Assisted feeding (syringe feeding or placement of a nasoesophageal tube) in severe cases

Management of VS-FCV

Cats with suspected virulent systemic FCV require intensive care:

• ·Hospitalization with barrier nursing and strict isolation protocols
• ·Aggressive intravenous fluid therapy
• ·Broad-spectrum antibiotics to prevent secondary bacterial infections
• ·Colloid therapy for hypoproteinemia
• ·Antiviral agents: Interferons (feline interferon-omega, where available) have been used empirically; evidence for efficacy remains limited

Antibiotic Use

Antibiotics are not indicated for uncomplicated FCV limping syndrome (viral etiology). They should be reserved for cases where secondary bacterial infection is documented or strongly suspected based on synovial fluid culture or clinical deterioration.

Uncomplicated Limping Syndrome

The prognosis for FCV-associated limping syndrome in its typical form is excellent. The vast majority of affected cats recover fully within 7–14 days with appropriate supportive care. Permanent joint damage is not a recognized sequela of uncomplicated cases, and cats are expected to return to normal function without long-term musculoskeletal sequelae. Recurrence is possible with re-exposure to FCV or reactivation of latent infection, but is uncommon.

Vaccine-Associated Cases

Post-vaccination limping syndrome carries a particularly favorable prognosis. Symptoms generally resolve spontaneously within 5–10 days, and no intervention beyond rest and analgesia is typically required. No long-term adverse outcomes have been associated with this form.

Virulent Systemic FCV

In contrast, the prognosis for cats infected with virulent systemic FCV strains is substantially worse. Reported case-fatality rates in VS-FCV outbreaks have ranged from approximately 33% to 67%, with some outbreak reports citing mortality exceeding 50% of infected cats. The high mortality in these outbreaks reflects multi-organ failure, hemorrhagic disease, and rapid clinical deterioration. Adult cats, including those previously vaccinated against FCV, are disproportionately represented among severe VS-FCV cases, underscoring that standard vaccination provides incomplete protection against these highly divergent strains.

Prognostic Indicators

Factors associated with a poorer prognosis include:

• ·Evidence of systemic involvement (hyperbilirubinemia, hypoalbuminemia, thrombocytopenia)
• ·Severe leukopenia on CBC
• ·Markedly elevated ALT suggesting hepatic involvement
• ·Skin ulceration or edema distant from oral cavity
• ·Failure to respond to initial supportive care within 48–72 hours

Data Limitation Note

Precise survival statistics specific to the limping/polyarthritis form of FCV (as distinct from VS-FCV) are not available in the peer-reviewed literature cited for this entry. The clinical consensus is that mortality for uncomplicated limping syndrome is very low (likely <5%), while VS-FCV mortality is well-recognized to be high.

Vaccination

Vaccination against FCV is considered a core component of feline preventive medicine and is recommended for all cats by major veterinary organizations (AAFP, WSAVA). Available vaccines include:

• ·Modified-live virus (MLV) vaccines: Highly immunogenic; however, they carry the low but recognized risk of inducing post-vaccination limping syndrome in kittens. Typically administered as combination vaccines (FVRCP: Feline Viral Rhinotracheitis, Calicivirus, Panleukopenia)
• ·Inactivated (killed) vaccines: Lower risk of adverse reactions including post-vaccination limping, though generally considered slightly less immunogenic than MLV formulations
• ·Vaccination schedule: Primary series of 2–3 doses given 3–4 weeks apart starting at 6–8 weeks of age; boosted at 1 year, then every 3 years in low-risk adult cats (or annually in high-risk environments per risk assessment)

Limitations of Vaccination

Given FCV's extensive antigenic diversity, no vaccine provides complete protection against all circulating strains. Vaccines significantly reduce the severity of disease but may not prevent infection or viral shedding entirely. VS-FCV strains in particular have caused outbreaks in vaccinated populations. Bivalent vaccines incorporating two different FCV strains are available and may broaden protective coverage.

Infection Control

• ·Isolation of new cats: Quarantine incoming cats for a minimum of 14 days before introduction to resident cats or shelter populations
• ·Environmental disinfection: FCV is relatively resistant in the environment but is inactivated by bleach (sodium hypochlorite) solutions at 1:32 dilution; thorough cleaning and disinfection of housing, food bowls, and shared equipment is essential
• ·Population management: Avoid overcrowding in shelters and catteries; adequate ventilation reduces aerosol transmission
• ·Identify and manage carrier cats: Chronically infected cats that shed FCV without clinical signs represent a reservoir; PCR testing can identify shedders in multi-cat environments
• ·Hand hygiene: Regular handwashing and use of gloves when handling cats with respiratory signs or known FCV-positive status prevents fomite transmission

Post-Vaccination Monitoring

Owners of recently vaccinated kittens, particularly those receiving MLV vaccines, should be advised to monitor for lameness or joint swelling in the days following vaccination. If post-vaccination limping is observed, a veterinary examination is warranted to confirm the likely self-limiting nature of the reaction and to provide analgesia if needed.